Abstract
Conventional radiotherapy or chemotherapy for the long-term survival of patients with lung cancer is still difficult for treatment in metastatic and advanced tumors. Therefore, the safe and effective approaches to the treatment of lung cancer are needed. In this study, the effect of delivered eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) on lung cancer progression was evaluated. Recombinant adeno-associated virus (rAAV)-M3/4E-BP1 was delivered into 6-week-old K-rasLA1 lung cancer model mice through a nose-only inhalation system twice a week for 4 weeks. Long-term repeated delivery of 4E-BP1 effectively reduced tumor progression in the lungs of K-rasLA1 mice. Reduction of eIF4E by overexpression of 4E-BP1 resulted in suppression of cap-dependent protein expression of basic fibroblast growth factor (bFGF or FGF-2) and vascular endothelial growth factor (VEGF). In addition, delivered 4E-BP1 inhibited the proliferation of lung cancer cells in K-rasLA1 mice model. Our results suggest that long-term repeated viral delivery of 4E-BP1 may provide a useful tool for designing lung cancer treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13: 1539–1549.
Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016–3024.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–1597.
Hwang SK, Lim HT, Minai-Tehrani A, Lee ES, Park J, Park SB et al. Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice. Am J Respir Crit Care Med 2009; 179: 1131–1140.
Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B et al. Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1. Int J Nanomedicine 2012; 7: 2293–2306.
Chang SH, Hong SH, Jiang HL, Minai-Tehrani A, Yu KN, Lee JH et al. GOLGA2/GM130, cis-golgi matrix protein, is a novel target of anticancer gene therapy. Mol Ther 2012; 20: 2052–2063.
Fujimura K, Sasaki AT, Anderson P . Selenite targets eIF4E-binding protein-1 to inhibit translation initiation and induce the assembly of non-canonical stress granules. Nucleic Acids Res 2012; 40: 8099–8110.
Rousseau D, Gingras AC, Pause A, Sonenberg N . The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996; 13: 2415–2420.
Kim YY, Von Weymarn L, Larsson O, Fan D, Underwood JM, Peterson MS et al. Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res 2009; 69: 8455–8462.
Sunavala-Dossabhoy G, Palaniyandi S, Clark C, Nathan CO, Abreo FW, Caldito G . Analysis of eIF4E and 4EBP1 mRNAs in head and neck cancer. Laryngoscope 2011; 121: 2136–2141.
Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212–4223.
Yu Y, Pilgrim P, Zhou W, Gagliano N, Frezza EE, Jenkins M et al. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol 2008; 21: 435–442.
Małecki M, Swoboda P, Pachecka J . Recombinant adeno-associated virus derived vectors (rAAV2) efficiently transduce ovarian and hepatocellular carcinoma cells—implications for cancer gene therapy. Acta Pol Pharm 2009; 66: 93–99.
Chen C, Sun J, Liu G, Chen J . Effect of small interference RNA targeting HIF-1alpha mediated by rAAV combined L-ascorbate on pancreatic tumors in athymic mice. Pathol Oncol Res 2009; 15: 109–114.
Goula D, Becker N, Lemkine GF, Normandie P, Rodrigues J, Mantero S et al. Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Therapy 2000; 7: 499–504.
Woo JK, Choi DS, Tran HT, Gilbert BE, Hong WK, Lee HY . Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev Res (Phila) 2009; 2: 361–369.
Wu F, Liu Y, Lv X, Miao X, Sun Y, Yu W . Small interference RNA targeting TLR4 gene effectively attenuates pulmonary inflammation in a rat model. J Biomed Biotechnol 2012; 2012: 406435.
Densmore CL . Advances in noninvasive pulmonary gene therapy. Curr Drug Deliv 2006; 3: 55–63.
Beck SE, Laube BL, Barberena CI, Fischer AC, Adams RJ, Chesnut K et al. Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. Mol Ther 2002; 6: 546–554.
Fischer AC, Beck SE, Smith CI, Laube BL, Askin FB, Guggino SE et al. Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther 2003; 8: 918–926.
Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509–521.
Park K, Seol W, Cho YH, Jeong S, Lee H . Cancer cell specific expression vector containing deleted mutant promoter of PRC1. Korean Pat 2010 10-2010-0007500.
Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N . mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416–6422.
Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10: 484–486.
Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS . Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996; 65: 785–790.
Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL . Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000; 82: 161–166.
Liang Z, Lei T, LuYing Z, YuPing G . The expression of proto-oncogene eIF4E in laryngeal squamous cell carcinoma. Laryngoscope 2003; 113: 1238–1243.
Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ, Swain SM . Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 2007; 17: 281–287.
Acknowledgements
Part of this work was supported by the National Research Foundation grant (2012M3A9B6055304) funded by the Korea government (MEST). M-HC was also partially supported by the Research Institute for Veterinary Science, Seoul National University, Seoul, Korea.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chang, SH., Kim, JE., Lee, JH. et al. Aerosol delivery of eukaryotic translation initiation factor 4E-binding protein 1 effectively suppresses lung tumorigenesis in K-rasLA1 mice. Cancer Gene Ther 20, 331–335 (2013). https://doi.org/10.1038/cgt.2013.24
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2013.24